Celgene | Search Results | Sutro Biopharma, Inc.

New Search

If you are not happy with the results below please do another search

Sutro Biopharma Reports Second Quarter 2019 Financial Results and Recent Business Highlights and Developments

August 14, 2019

STRO-001 Initial Safety Data from an Ongoing Phase 1 Trial in Myeloma and Lymphoma presented at the European Hematology Association (“EHA”) Congress, June 15, 2019 STRO-002 Phase 1 Clinical Trial... read more →

Sutro Biopharma to Present at the 2019 Wedbush PacGrow Healthcare Conference

August 8, 2019

SOUTH SAN FRANCISCO, Calif., Aug. 8, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and... read more →

Sutro Biopharma Appoints Biopharma Veteran Connie Matsui as Board Chair

June 24, 2019

Former Biogen Idec executive to bring additional strategic expertise to Sutro’s Board SOUTH SAN FRANCISCO, Calif., June 24, 2019 -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development... read more →

Sutro Biopharma to Present at the JMP Securities Life Sciences Conference

June 18, 2019

SOUTH SAN FRANCISCO, Calif., June 18, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and... read more →

Sutro Biopharma Announces Encouraging Interim Phase 1 Safety Data on a Potential First-in-Class Antibody-Drug Conjugate STRO-001 for the Treatment of B-cell Malignancies at the European Hematology Association Congress

June 15, 2019

Sutro Biopharma Announces Encouraging Interim Phase 1 Safety Data on a Potential First-in-Class Antibody-Drug Conjugate STRO-001 for the Treatment of B-cell Malignancies at the European Hematology Association Congress Interim results... read more →

Sutro Biopharma Announces Presentation at the 2019 European Hematology Association Congress

May 16, 2019

SOUTH SAN FRANCISCO, Calif., May 16, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that the company will present at the upcoming European Hematology Association (EHA) Congress being held... read more →

Sutro Biopharma Reports First Quarter 2019 Financial Results and Recent Business Highlights and Developments

May 15, 2019

STRO-001 Ongoing Phase 1 Trial in Myeloma and Lymphoma with Initial Safety Data to be presented at the European Hematology Association (“EHA”) Congress, June 15, 2019 STRO-002 Phase 1 Clinical... read more →

Sutro Biopharma Reports Full Year 2018 Financial Results and Recent Business Highlights and Developments

April 1, 2019

STRO-001 Ongoing Phase 1 Trial in Myeloma and Lymphoma with Initial Safety Data Expected Mid-2019 STRO-002 Phase 1 Clinical Trial Initiated in Ovarian and Endometrial Cancers SOUTH SAN FRANCISCO, Calif., April... read more →

Sutro Achieves $10 Million Milestone Payment from Celgene

December 19, 2018

Sutro Achieves $10 Million Milestone Payment from Celgene Sutro develops successful spray drying technology marking a major advancement in commercial-scale manufacturing capabilities SOUTH SAN FRANCISCO, Calif., Dec. 19, 2018 --... read more →

Sutro Biopharma Reports Third Quarter 2018 Financial Results

November 14, 2018

-- STRO-001 Received Orphan Drug Designation for Treatment of Multiple Myeloma -- STRO-002 to Begin Phase 1 Trial for Patients with Ovarian and Endometrial Cancers in Early 2019 SOUTH SAN... read more →

26 Search results for: Celgene

New Search